Possible drug-drug interaction between adalimumab and duloxetine and/or pregabalin in a psoriasis patient

J Drugs Dermatol. 2013 Oct;12(10):1089.
No abstract available

Publication types

  • Case Reports
  • Editorial

MeSH terms

  • Adalimumab
  • Analgesics / adverse effects*
  • Analgesics / therapeutic use
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antidepressive Agents / adverse effects*
  • Antidepressive Agents / therapeutic use
  • Biological Products / therapeutic use
  • Cytochrome P-450 Enzyme System / metabolism
  • Diabetes Mellitus, Type 1 / complications
  • Diabetic Neuropathies / complications
  • Diabetic Neuropathies / drug therapy
  • Drug Interactions
  • Duloxetine Hydrochloride
  • Female
  • Humans
  • Pregabalin
  • Psoriasis / complications*
  • Psoriasis / drug therapy
  • Thiophenes / adverse effects*
  • Thiophenes / therapeutic use
  • Young Adult
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Analgesics
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Antidepressive Agents
  • Biological Products
  • Thiophenes
  • Pregabalin
  • gamma-Aminobutyric Acid
  • Cytochrome P-450 Enzyme System
  • Duloxetine Hydrochloride
  • Adalimumab